{"pmid":32304343,"title":"Bilirubin levels in patients with mild and severe Covid-19: a pooled analysis.","text":["Bilirubin levels in patients with mild and severe Covid-19: a pooled analysis.","The letter comments on a recent commentary published in Liver International entitled \"COVID-19 and liver disease\" by Sun et al., and describes a pooled analysis of data on bilirubin levels in patients with and without severe Covid-19. This is the first pooled analysis of data on bilirubin in Covid-19 patients. The results evidence that bilirubin levels are significantly associated with the severity of the disease.","Liver Int","Paliogiannis, Panagiotis","Zinellu, Angelo","32304343"],"abstract":["The letter comments on a recent commentary published in Liver International entitled \"COVID-19 and liver disease\" by Sun et al., and describes a pooled analysis of data on bilirubin levels in patients with and without severe Covid-19. This is the first pooled analysis of data on bilirubin in Covid-19 patients. The results evidence that bilirubin levels are significantly associated with the severity of the disease."],"journal":"Liver Int","authors":["Paliogiannis, Panagiotis","Zinellu, Angelo"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304343","week":"202016|Apr 13 - Apr 19","doi":"10.1111/liv.14477","source":"PubMed","topics":["Diagnosis"],"weight":1,"e_drugs":["Bilirubin"],"_version_":1664431720496103424,"score":8.233237,"similar":[{"pmid":32239591,"title":"Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injuryA Retrospective study.","text":["Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injuryA Retrospective study.","BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has raised world concern for global epidemic since December, 2019. Limited data are available for liver function in COVID-19 patients. We aimed to investigate the risk factors related to liver injury in the COVID-19 patients. METHODS: A retrospective study was performed in Non-ICU Ward at Jinyintan Hospital from February 2, 2020 to February 23, 2020. Consecutively confirmed COVID-19 discharged cases were enrolled. The clinical characteristics of patients with liver injury and without liver injury were compared. RESULTS: A total of 79 COVID-19 patients were included. 31.6%, 35.4% and 5.1% COVID-19 patients had elevated levels of ALT, AST and bilirubin, respectively. Median value of ALT, AST and bilirubin for entire cohort were 36.5 (17.5~71.5) U/L, 34.5 (25.3~ 55.3) U/L and 12.7 (8.1~15.4) mmol/L, respectively. There were no significant differences in age, previous medical history, and symptoms between the two groups. Males were more likely to have liver injury when infected with COVID-19 (p<0.05); Compared to patients without liver injury, patients with liver injury had increased levels of white blood cell counts, neutrophils, CRP and CT score (p< 0.05), and had a longer length of stay (p< 0.05). Logistic regression analyses suggested that the extent of pulmonary lesions on CT was a predictor of liver function damage (p< 0.05). CONCLUSIONS: Liver injury is common in Non-ICU hospitalized COVID-19 patients. It may be related to systemic inflammation. Intense monitoring and evaluation of liver function in patients with severe pulmonary imaging lesions should be considered.","Liver Int","Xie, Hansheng","Zhao, Jianming","Lian, Ningfang","Lin, Su","Xie, Qunfang","Zhuo, Huichang","32239591"],"abstract":["BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has raised world concern for global epidemic since December, 2019. Limited data are available for liver function in COVID-19 patients. We aimed to investigate the risk factors related to liver injury in the COVID-19 patients. METHODS: A retrospective study was performed in Non-ICU Ward at Jinyintan Hospital from February 2, 2020 to February 23, 2020. Consecutively confirmed COVID-19 discharged cases were enrolled. The clinical characteristics of patients with liver injury and without liver injury were compared. RESULTS: A total of 79 COVID-19 patients were included. 31.6%, 35.4% and 5.1% COVID-19 patients had elevated levels of ALT, AST and bilirubin, respectively. Median value of ALT, AST and bilirubin for entire cohort were 36.5 (17.5~71.5) U/L, 34.5 (25.3~ 55.3) U/L and 12.7 (8.1~15.4) mmol/L, respectively. There were no significant differences in age, previous medical history, and symptoms between the two groups. Males were more likely to have liver injury when infected with COVID-19 (p<0.05); Compared to patients without liver injury, patients with liver injury had increased levels of white blood cell counts, neutrophils, CRP and CT score (p< 0.05), and had a longer length of stay (p< 0.05). Logistic regression analyses suggested that the extent of pulmonary lesions on CT was a predictor of liver function damage (p< 0.05). CONCLUSIONS: Liver injury is common in Non-ICU hospitalized COVID-19 patients. It may be related to systemic inflammation. Intense monitoring and evaluation of liver function in patients with severe pulmonary imaging lesions should be considered."],"journal":"Liver Int","authors":["Xie, Hansheng","Zhao, Jianming","Lian, Ningfang","Lin, Su","Xie, Qunfang","Zhuo, Huichang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32239591","week":"202014|Mar 30 - Apr 05","doi":"10.1111/liv.14449","keywords":["COVID-19","liver injury","pulmonary lesions","systemic inflammation"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"e_drugs":["Bilirubin"],"_version_":1663352135545257984,"score":214.55379},{"pmid":32153170,"title":"[Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region].","text":["[Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region].","Objective: To understand the clinical characteristics, change of liver function, influencing factors and prognosis in hospitalized patients with coronavirus disease-19 (COVID-19) combined with liver injury. Methods: The general conditions, biochemical indicators of liver, blood clotting mechanism, routine blood test, UGT1A1 * 28 gene polymorphism and other data of 40 cases with COVID-19 admitted to the isolation ward of Tangdu Hospital were retrospectively analyzed. The clinical characteristics, influencing factors and prognosis of liver injury in patients with liver injury group and those with normal liver function group were compared. The mean of two samples in univariate analysis was compared by t-test and analysis of variance. The counting data was measured by chi(2) tests. The non-normal distribution measurement data were described by the median, and the non-parametric test was used. Statistically significant influencing factors were used as the independent variables in univariate analysis. Multiple logistic regression analysis was used to analyze the main influencing factors of liver injury. Results: Of the 40 cases, 25 were male (62.5%) and 15 were female (37.5%), aged 22 to 83 (53.87 +/- 15.84) years. Liver injury was occurred in 22 cases (55%) during the course of the disease. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level was initially increased (4.4 to 3.5 times of the normal value) along with decrease of albumin in the second week, and the difference was statistically significant (P < 0.001). Ten cases (43.5%) had highest abnormal total blood bilirubin (54.1 mumol/ L). There was no correlation between the increase in transaminase and the increase in total blood bilirubin (R = -0.006, P = 0.972). Three cases had prothrombin activity (PTA) of </= 50%, 10 cases had elevated FDP, and 13 cases had elevated D-dimer, all of whom were severe or critically ill. Liver function injury was more likely to occur in patients who used many types of drugs and large amounts of hormones (P = 0.002, P = 0.031), and there was no correlation with the TA6TA7 mutation in the UGT1A1 * 28 gene locus. Multiple regression analysis showed that the occurrence of liver injury was only related to critical illness. The liver function of all patients had recovered within one week after conventional liver protection treatment. Conclusion: COVID-19 combined with liver function injury may be due to the slight elevation of transaminase, mostly around the second week of the disease course. Severe patients have a higher proportion of liver injury, and critical type is an independent risk factor for liver injury.","Zhonghua Gan Zang Bing Za Zhi","Yao, N","Wang, S N","Lian, J Q","Sun, Y T","Zhang, G F","Kang, W Z","Kang, W","32153170"],"abstract":["Objective: To understand the clinical characteristics, change of liver function, influencing factors and prognosis in hospitalized patients with coronavirus disease-19 (COVID-19) combined with liver injury. Methods: The general conditions, biochemical indicators of liver, blood clotting mechanism, routine blood test, UGT1A1 * 28 gene polymorphism and other data of 40 cases with COVID-19 admitted to the isolation ward of Tangdu Hospital were retrospectively analyzed. The clinical characteristics, influencing factors and prognosis of liver injury in patients with liver injury group and those with normal liver function group were compared. The mean of two samples in univariate analysis was compared by t-test and analysis of variance. The counting data was measured by chi(2) tests. The non-normal distribution measurement data were described by the median, and the non-parametric test was used. Statistically significant influencing factors were used as the independent variables in univariate analysis. Multiple logistic regression analysis was used to analyze the main influencing factors of liver injury. Results: Of the 40 cases, 25 were male (62.5%) and 15 were female (37.5%), aged 22 to 83 (53.87 +/- 15.84) years. Liver injury was occurred in 22 cases (55%) during the course of the disease. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level was initially increased (4.4 to 3.5 times of the normal value) along with decrease of albumin in the second week, and the difference was statistically significant (P < 0.001). Ten cases (43.5%) had highest abnormal total blood bilirubin (54.1 mumol/ L). There was no correlation between the increase in transaminase and the increase in total blood bilirubin (R = -0.006, P = 0.972). Three cases had prothrombin activity (PTA) of </= 50%, 10 cases had elevated FDP, and 13 cases had elevated D-dimer, all of whom were severe or critically ill. Liver function injury was more likely to occur in patients who used many types of drugs and large amounts of hormones (P = 0.002, P = 0.031), and there was no correlation with the TA6TA7 mutation in the UGT1A1 * 28 gene locus. Multiple regression analysis showed that the occurrence of liver injury was only related to critical illness. The liver function of all patients had recovered within one week after conventional liver protection treatment. Conclusion: COVID-19 combined with liver function injury may be due to the slight elevation of transaminase, mostly around the second week of the disease course. Severe patients have a higher proportion of liver injury, and critical type is an independent risk factor for liver injury."],"journal":"Zhonghua Gan Zang Bing Za Zhi","authors":["Yao, N","Wang, S N","Lian, J Q","Sun, Y T","Zhang, G F","Kang, W Z","Kang, W"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32153170","week":"202011|Mar 09 - Mar 15","doi":"10.3760/cma.j.cn501113-20200226-00070","keywords":["COVID-19","Clinical characteristics","Liver function","Liver injury","Prognosis","Risk factor"],"source":"PubMed","locations":["Shaanxi"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"e_drugs":["Bilirubin"],"_version_":1663352134100320256,"score":212.94763},{"pmid":32298767,"title":"Characteristics of Liver Tests in COVID-19 Patients.","text":["Characteristics of Liver Tests in COVID-19 Patients.","BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver tests. METHODS: Clinical records and laboratory results were obtained from 417 laboratory-confirmed COVID-19 patients who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information of clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients raising liver enzyme levels to more than 3 times of upper limit units in alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase, respectively. Patients with abnormal liver test of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios (OR)=2.73, 95% confidence interval (CI) 1.19-6.3, and 4.44, 95% CI 1.93-10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both P<0.01). CONCLUSION: Patients with abnormal liver tests had higher risks of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, should be monitored and evaluated frequently.","J Hepatol","Cai, Qingxian","Huang, Deliang","Yu, Hong","Zhu, Zhibin","Xia, Zhang","Su, Yinan","Li, Zhiwei","Zhou, Guangde","Gou, Jizhou","Qu, Jiuxin","Sun, Yan","Liu, Yingxia","He, Qing","Chen, Jun","Liu, Lei","Xu, Lin","32298767"],"abstract":["BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver tests. METHODS: Clinical records and laboratory results were obtained from 417 laboratory-confirmed COVID-19 patients who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information of clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients raising liver enzyme levels to more than 3 times of upper limit units in alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase, respectively. Patients with abnormal liver test of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios (OR)=2.73, 95% confidence interval (CI) 1.19-6.3, and 4.44, 95% CI 1.93-10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both P<0.01). CONCLUSION: Patients with abnormal liver tests had higher risks of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, should be monitored and evaluated frequently."],"journal":"J Hepatol","authors":["Cai, Qingxian","Huang, Deliang","Yu, Hong","Zhu, Zhibin","Xia, Zhang","Su, Yinan","Li, Zhiwei","Zhou, Guangde","Gou, Jizhou","Qu, Jiuxin","Sun, Yan","Liu, Yingxia","He, Qing","Chen, Jun","Liu, Lei","Xu, Lin"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298767","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jhep.2020.04.006","keywords":["COVID-19","Liver Tests","Liver injury","SARS-Cov-2"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Shenzhen","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266651172864000,"score":201.69785},{"pmid":32231171,"title":"Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis.","text":["Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis.","INTRODUCTION: As the coronavirus disease 2019 (COVID-19) outbreak, identification of clinical predictors of severe or fatal disease are necessary to enable risk stratification and optimize allocation of limited resources. Hypertension has been widely reported to be associated with increase disease severity, however, other studies have reported different findings. OBJECTIVES: To evaluate the association of hypertension and severe and fatal COVID-19. PATIENTS AND METHODS: Scopus, Medline, and Web of Science was performed to identify studies reporting the rate of hypertension in COVID-19 patients with severe or non-severe disease or among survivors and non-survivors. The obtained data was pooled into a meta-analysis to calculate odds ratio (OR) with 95% confidence intervals (95%CI). RESULTS: Hypertension was associated with a nearly 2.5-fold significantly increased risk of severe COVID-19 disease (OR: 2.49 [95%CI: 1.98-3.12] I2=24%), as well as with a similarly significant higher risk of mortality (OR: 2.42 [95%CI: 1.51-3.90] I2=0%). In meta-regression, a significant correlation was observed with an increase in mean age of patients with severe COVID-19 associated with increased log odds of hypertension and severity (p=0.03). CONCLUSIONS: The results of this pooled analysis of the current scientific literature would suggest that hypertension may be associated with an up to 2.5-fold higher risk of severe and fatal COVID-19, especially among older individuals.","Pol Arch Intern Med","Lippi, Giuseppe","Wong, Johnny","Henry, Brandon Michael","32231171"],"abstract":["INTRODUCTION: As the coronavirus disease 2019 (COVID-19) outbreak, identification of clinical predictors of severe or fatal disease are necessary to enable risk stratification and optimize allocation of limited resources. Hypertension has been widely reported to be associated with increase disease severity, however, other studies have reported different findings. OBJECTIVES: To evaluate the association of hypertension and severe and fatal COVID-19. PATIENTS AND METHODS: Scopus, Medline, and Web of Science was performed to identify studies reporting the rate of hypertension in COVID-19 patients with severe or non-severe disease or among survivors and non-survivors. The obtained data was pooled into a meta-analysis to calculate odds ratio (OR) with 95% confidence intervals (95%CI). RESULTS: Hypertension was associated with a nearly 2.5-fold significantly increased risk of severe COVID-19 disease (OR: 2.49 [95%CI: 1.98-3.12] I2=24%), as well as with a similarly significant higher risk of mortality (OR: 2.42 [95%CI: 1.51-3.90] I2=0%). In meta-regression, a significant correlation was observed with an increase in mean age of patients with severe COVID-19 associated with increased log odds of hypertension and severity (p=0.03). CONCLUSIONS: The results of this pooled analysis of the current scientific literature would suggest that hypertension may be associated with an up to 2.5-fold higher risk of severe and fatal COVID-19, especially among older individuals."],"journal":"Pol Arch Intern Med","authors":["Lippi, Giuseppe","Wong, Johnny","Henry, Brandon Michael"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32231171","week":"202014|Mar 30 - Apr 05","doi":"10.20452/pamw.15272","source":"PubMed","locations":["p=0.03"],"topics":["Diagnosis"],"weight":1,"_version_":1663352135408943105,"score":178.96107},{"pmid":32283325,"title":"Clinical Features of COVID-19-Related Liver Damage.","text":["Clinical Features of COVID-19-Related Liver Damage.","BACKGROUND & AIMS: Some patients with SARS-CoV-2 infection have abnormal liver function. We aimed to clarify the features of COVID-19-related liver damage to provide references for clinical treatment. METHODS: We performed a retrospective, single-center study of 148 consecutive patients with confirmed COVID-19 (73 female, 75 male; mean age, 50 years) at the Shanghai Public Health Clinical Center from January 20 through January 31, 2020. Patient outcomes were followed until February 19, 2020. Patients were analyzed for clinical features, laboratory parameters (including liver function tests), medications, and length of hospital stay. Abnormal liver function was defined as increased levels of alanine and aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, and total bilirubin. RESULTS: Fifty-five patients (37.2%) had abnormal liver function at hospital admission; 14.5% of these patients had high fever (14.5%), compared with 4.3% of patients with normal liver function (P=.027). Patients with abnormal liver function were more likely to be male, and had higher levels of procalcitonin and C-reactive protein. There was no statistical difference between groups in medications taken before hospitalization; a significantly higher proportion of patients with abnormal liver function (57.8%) had received lopinavir/ritonavir after admission compared to patients with normal liver function (31.3%). Patients with abnormal liver function had longer mean hospital stays (15.09+/-4.79 days) than patients with normal liver function (12.76+/-4.14 days) (P=.021). CONCLUSIONS: More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution.","Clin Gastroenterol Hepatol","Fan, Zhenyu","Chen, Liping","Li, Jun","Cheng, Xin","Jingmao Yang","Tian, Cheng","Zhang, Yajun","Huang, Shaoping","Liu, Zhanju","Cheng, Jilin","32283325"],"abstract":["BACKGROUND & AIMS: Some patients with SARS-CoV-2 infection have abnormal liver function. We aimed to clarify the features of COVID-19-related liver damage to provide references for clinical treatment. METHODS: We performed a retrospective, single-center study of 148 consecutive patients with confirmed COVID-19 (73 female, 75 male; mean age, 50 years) at the Shanghai Public Health Clinical Center from January 20 through January 31, 2020. Patient outcomes were followed until February 19, 2020. Patients were analyzed for clinical features, laboratory parameters (including liver function tests), medications, and length of hospital stay. Abnormal liver function was defined as increased levels of alanine and aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, and total bilirubin. RESULTS: Fifty-five patients (37.2%) had abnormal liver function at hospital admission; 14.5% of these patients had high fever (14.5%), compared with 4.3% of patients with normal liver function (P=.027). Patients with abnormal liver function were more likely to be male, and had higher levels of procalcitonin and C-reactive protein. There was no statistical difference between groups in medications taken before hospitalization; a significantly higher proportion of patients with abnormal liver function (57.8%) had received lopinavir/ritonavir after admission compared to patients with normal liver function (31.3%). Patients with abnormal liver function had longer mean hospital stays (15.09+/-4.79 days) than patients with normal liver function (12.76+/-4.14 days) (P=.021). CONCLUSIONS: More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution."],"journal":"Clin Gastroenterol Hepatol","authors":["Fan, Zhenyu","Chen, Liping","Li, Jun","Cheng, Xin","Jingmao Yang","Tian, Cheng","Zhang, Yajun","Huang, Shaoping","Liu, Zhanju","Cheng, Jilin"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283325","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.cgh.2020.04.002","keywords":["ALP","Antiviral drug","Prognosis","liver injury"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"e_drugs":["lopinavir-ritonavir drug combination"],"_version_":1664182200818466816,"score":173.76666}]}